Shares of Radius Health took a nosedive on Thursday after the Waltham biotech revealed early-stage data on a breast cancer drug showing partial responses by a relatively small number of patients. Radius Health CEO Robert Ward previously said during a Nov. 3 earnings call that the company had observed “multiple confirmed clinical responses” during two ongoing Phase 1 studies of the treatment, called RAD1901.

Topics:  waltham   radius health ceo robert ward   nov   phase   rad1901   radius health   shares   cancer   data   thursday   responses   number   

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News